(Q44769690)

6 December 2017

title

Mepolizumab treatment for asthma (English)

1 reference

6 December 2017

0 references

1 reference

Douglas S Robinson

1

1 reference

6 December 2017

language of work or name

English

0 references

publication date

24 September 2012

1 reference

Expert Opinion on Biological Therapy

6 December 2017

published in

1 reference

6 December 2017

volume

13

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

295-302

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

6 December 2017

1 reference

Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Burden of allergic disease in the UK: secondary analyses of national databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Cluster analysis and clinical asthma phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

The role of the T cell in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Omalizumab in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Evidence of a role of tumor necrosis factor alpha in refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Eosinophils in asthma--closing the loop or opening the door?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Mepolizumab in refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

Severe asthma treatment: need for characterising patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.725717

10.1517/14712598.2012.725717

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference